RESUMO
HLA-C*01:166 has a nonsynonymous nucleotide substitution in the position 256 position (C/T) when compared to C*01:02:01:01.
Assuntos
Doadores de Sangue , Sangue Fetal , Antígenos HLA-C/genética , Alelos , Colômbia , Transplante de Células-Tronco de Sangue do Cordão Umbilical , Feminino , Teste de Histocompatibilidade , Humanos , Família Multigênica , Polimorfismo GenéticoRESUMO
HLA-B*18:147 differs from HLA-B*18:01:01:01 by one nucleotide substitution.
Assuntos
Bancos de Sangue , Sangue Fetal , Antígeno HLA-B18/genética , Mutação Puntual , Colômbia , HumanosRESUMO
Two novel HLA-class I alleles discovered: HLA-C*08:162 and HLA-C*03:296:02.
Assuntos
Doadores de Sangue , Transplante de Células-Tronco de Sangue do Cordão Umbilical , Sangue Fetal/metabolismo , Antígenos HLA-C/genética , Teste de Histocompatibilidade/métodos , Polimorfismo de Nucleotídeo Único , Análise de Sequência de DNA/métodos , Sequência de Bases , Bancos de Espécimes Biológicos , Colômbia , Humanos , Homologia de SequênciaRESUMO
This was a case study in which 3 patients with autoimmune/auto-inflammatory syndrome induced by adjuvants (ASIA) after quadrivalent human papillomavirus vaccination (HPV) were evaluated and described. All the patients were women. Diagnosis consisted of HLA-B27 enthesitis related arthritis, rheumatoid arthritis and systemic lupus erythematous, respectively. Our results highlight the risk of developing ASIA after HPV vaccination and may serve to increase the awareness of such a complication. Factors that are predictive of developing autoimmune diseases should be examined at the population level in order to establish preventive measures in at-risk individuals for whom healthcare should be personalized and participatory.
Assuntos
Adjuvantes Imunológicos/efeitos adversos , Artrite Juvenil , Artrite Reumatoide , Lúpus Eritematoso Sistêmico , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/efeitos adversos , Neoplasias do Colo do Útero/prevenção & controle , Adjuvantes Imunológicos/administração & dosagem , Adolescente , Antirreumáticos/administração & dosagem , Artrite Juvenil/etiologia , Artrite Juvenil/imunologia , Artrite Juvenil/fisiopatologia , Artrite Juvenil/terapia , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/etiologia , Artrite Reumatoide/imunologia , Artrite Reumatoide/fisiopatologia , Autoanticorpos/sangue , Feminino , Glucocorticoides/administração & dosagem , Antígeno HLA-B27/sangue , Humanos , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Lúpus Eritematoso Sistêmico/etiologia , Lúpus Eritematoso Sistêmico/imunologia , Lúpus Eritematoso Sistêmico/fisiopatologia , Vacinas contra Papillomavirus/administração & dosagem , Resultado do Tratamento , Adulto JovemRESUMO
The Plasmodium merozoite surface antigen 2 (MSA2) is one of several candidates for a protective vaccine against malaria. Previous studies have shown that antibodies directed against the MSA2 variable region are not protective and that constant regions are non-immunogenic. However, modified peptides derived from constant regions can be rendered immunogenic and partially protective in Aotus monkeys. In this study, we reveal the establishment, using in vitro Herpesvirus samiri (HVS) infection, of an Aotus monkey T-cell line (AnTMSA2) specific for a modified immunogenic and partially protective peptide derived from a constant and highly conserved region of MSA2 (SKYSNTFINNAYNMSIRRSM). AnTMSA2 is a CD4 T lymphocyte expressing high levels of MHC class II molecules, CD58 and CD2, which are important for proliferation and growth. AnTMSA2 proliferates specifically in response to the modified monomeric MSA2 peptide sequence. It is also capable of specific antigen recognition after glycine-cysteine-polymerized sequence processing and presentation by autologous APC. Interestingly, AnTMSA2 presents cross-reactivity with D-peptide analogues in which residues in positions 8 and 9 were changed for NDID residues. Therefore, at least for this particular sequence, polymerized D-peptides could be used for immunizing animals without losing the immunogenic epitope. AnTMSA2 presents a cytokine profile corresponding to a Th0-like pattern, which suggests that as a result of HVS immortalization AnTMSA2 is in transit from a Th2 to a Th1 pattern. Taken together our results suggest that Th2 T-cell induction and/or T-cell cross-reactivity generation by the modified peptide could be responsible for the immunogenic conversion observed in Aotus monkeys and that D-peptide analogues with longer half-lives could provide an alternative for inducing protective immunity.